Genetics implicate common mechanisms in autism and schizophrenia: synaptic activity and immunity

Xiaoming Liu,1 Zhengwei Li,2 Conghai Fan,1 Dongli Zhang,1 Jiao Chen1

ABSTRACT
The diagnosis of debilitating psychiatric disorders like autism spectrum disorder (ASD) and schizophrenia (SCHZ) is on the rise. These are severe conditions that lead to social isolation and require lifelong professional care. Improved diagnosis of ASD and SCHZ provides early access to medication and therapy, but the reality is that the mechanisms and the cellular pathology underlying these conditions are mostly unknown at this time. Although both ASD and SCHZ have strong inherited components, genetic risk seems to be distributed in hundreds of variants, each conferring low risk. The poor understanding of the genetics of ASD and SCHZ is a significant hurdle to developing effective treatments for these costly conditions. The recent implementation of next-generation sequencing technologies and the creation of large consortia have started to reveal the genetic bases of ASD and SCHZ. Alterations in gene expression regulation, synaptic architecture and activity and immunity seem to be the main cellular mechanisms contributing to both ASD and SCHZ, a surprising overlap given the distinct phenotypes and onset of these conditions. These diverse pathways seem to converge in aberrant synaptic plasticity and remodelling, which leads to altered connectivity between relevant brain regions. Continuous efforts to understand the genetic basis of ASD and SCHZ will soon lead to significant progress in the mechanistic understanding of these prominent psychiatric disorders and enable the development of disease-modifying therapies for these devastating conditions.

INTRODUCTION
Recent years have witnessed a dramatic increase in the diagnosis of psychiatric disorders, including autism spectrum disorder (ASD), schizophrenia (SCHZ), attention deficit hyperactivity disorder (ADHD) and intellectual disability (ID), major mood disorders and bipolar disorder. This increase is in part due to more inclusive definitions and increased attention by parents, educators and clinicians. In particular, the rate of autism among infants has reached the level of epidemics with a significant burden caused by these conditions. The treatments currently available only address the most salient symptoms, but not the underlying problems. Since ASD, SCHZ, ADHD and ID have developmental components, early diagnosis and psychosocial interventions have the potential to partially correct or limit the deficits. However, disease-modifying treatments that specifically target the molecular and cellular pathologies triggering the symptoms will only be realised after reaching a deeper understanding of the mechanisms mediating these psychiatric disturbances. And this understanding will only come from identifying the genetic and environmental factors triggering these conditions. Here, we will review recent advances in the genetics of ASD and SCHZ pointing to common pathogenic mechanisms due to aberrant gene expression, synaptic activity and, surprisingly, immune function. These emerging mechanisms provide renewed hope for the development of targeted and effective treatments in the near future.

One avenue for treating human conditions consists on trying available drugs based on shared phenotypes (symptoms) with other diseases. Although this approach can provide symptomatic relief, it does not treat all the symptoms or the underlying pathology. In extreme cases, the treatment may be partially effective but have deleterious effects, making this approach suboptimal for chronic treatments. The ideal way to treat a disease is to first understand the molecular mechanisms causing the pathology because this knowledge will identify molecular targets at the core of the pathology with the potential to reverse most of the symptoms with the least side effects. In the age of genomics, the best approach to uncover the molecular basis of human disease is to identify the genes whose variants cause the disease (monogenic) or contribute to disease risk (polygenic). Both ASD and SCHZ have strong genetic components (around 50% heritability) as indicated by twin studies, in which around 89% of the risk comes from genetics.4–7 These observations suggest that a few rare and highly penetrant causative variants explain large fractions of heritability. However, for many years traditional genetic mapping studies and more recent genome-wide association studies (GWAS), which enables scanning entire genomes for variants associated with disease risk, failed to identify statistically significant hits in ASD and SCHZ. This scenario was frustrating for researchers and the affected families because strategies that explained other complex brain conditions did not work in ASD and SCHZ. At the same time, no specific environmental factors proved to be causative for these conditions, thus failing to explain the origin and mechanisms of these prevalent and debilitating conditions.
The situation changed with the establishment of large-scale international collaborations like the Psychiatric Genomics Consortium (PGC) that pooled many small cohorts to increase the power of prediction. The PGC also developed a Psych Chip at a cost of $50 per patient containing 60,000 common and rare variants previously implicated in SCHZ that fell short of statistical significance as well as genes within CNVs (including deletions and duplications) of interest. The last few years have yielded dramatic advances in the genetic bases of ASD and SCHZ with the identification of a few rare variants with high penetrance and a number of common variants in key pathways controlling gene expression, synaptic activity and immune function. The potential functional connections between these different pathways in brain development and synaptic function can explain the developmental components of ASD and SCHZ.

**ASD pathology**

ASD includes a continuum of conditions that manifest in early childhood characterised by impaired social communication, lack of interest and repetitive behaviours. Patients with autism often suffer ID, epilepsy, motor problems, ADHD, anxiety, sleep alterations and digestive issues. Over the last decade, autism has received heightened attention due to the continuous increase in diagnosis (reaching 1% in children worldwide), vocal advocacy and misguided attention towards vaccines. The distribution of ASD by gender is highly heterogeneous, with recent estimates suggesting that up to 1 in 42 boys and 1 in 189 girls are affected in the USA. Autism is also part of the clinical presentation of other (syndromic) conditions, including Rett syndrome, fragile X syndrome, tuberous sclerosis, neurofibromatosis and phos- phatase and tensin homologue (PTEN) macrocephaly. These conditions, although highly complex, account for 5%–7% of all autism cases and their known monogenetic origin can contribute to the discovery of the molecular basis underpinning autism (see below).

ASD is proposed to be caused by abnormal brain growth and connectivity; unfortunately, the brains of patients with ASD show no specific morphological abnormalities’ or cellular pathology that can support that theory. So far, the mechanisms disturbing neural communication and sensory integration remain to be discovered. Due to the lack of specific knowledge of the pathophysiology of ASD, the only available treatments include behavioural therapy, which works well for some patients and drugs that treat some of the symptoms, like risperidone for the aggressive and repetitive behaviour and aripiprazole to control irritability. However, no therapies treat the social interaction deficits that are at the core of autism, creating a big gap that can be bridged with improved understanding of ASD genetics.

**Genetics of ASD**

Twin studies find 60%–90% concordance for ASD, supporting a strong genetic component to ASD risk. Overall, heritability is around 50% with the environment contributing the other 50%. Despite this strong genetic contribution, identifying genes causative of ASD has been challenging.

One important clue to ASD pathogenesis comes from syndromic conditions that have autism as part of complex syndromes. Several of these conditions are caused by mutations in single genes, including methyl-CpG-binding protein 2 (MECP2) in Rett syndrome, fragile X mental retardation 1 (FMR1) in fragile X syndrome, tuberous sclerosis 1 (TSC1) or TSC2 in tuberous sclerosis, neurofibromin 1 (NF1) in neurofibromatosis and PTEN in PTEN macrocephaly. These six monogenic triggers of autism (among other symptoms) provide direct clues about the molecular basis of ASD. TSC1, TSC2 and PTEN are signalling molecules that regulate cell growth and other activities, and NF1 encodes a Ras inhibitor with pleiotropic activities in the cell. We will describe in more detail the role of MECP2 and FMRP in the regulation of gene expression. In all, altered gene expression and cell signalling can perturb early brain development and cause ASD, but the wide range of substrates for each of these regulatory genes hinders the identification of the specific developmental alterations that lead to ASD. In addition, the contributions of these genes to autism may be confounded with many other developmental abnormalities.

Except for these syndromic ASD genes, recent efforts have identified large numbers of genes (more than 1000) that contribute to ASD risk (reviewed in ref. 10). However, no single gene with strong contribution to autism has been identified so far. The genetic findings suggest that ASD is associated with hundreds of rare variants and around 100 common variants with small effects each. These variants are single-nucleotide polymorphisms (SNPs) and CNVs, but few are known to be causative and the genes associated with them remain mostly unknown. Most CNVs are found in a single patient, but three regions (15q11-q13, 16p11 and 22q11) have been found in many cases suggesting the inclusion of one of more relevant genes in those regions. Patients with ASD also show an increase in de novo variants, including rare mutations with high penetrance, and CNVs compared with the normal population. Interestingly, some patients carry more than one CNV, supporting a multiple hit model for autism.

The increased frequency of de novo mutations and CNVs in ASD supports a major contribution of a few genes (oligogenic model). But the contribution of de novo mutations to heritability seems to be overestimated. The picture that emerges so far for ASD supports a polygenic model where the additive effect of several variants causes disease, with the main contribution arising from common variants and a minor contribution coming from rare and de novo variants in combination with environmental factors. This model is consistent with a complex disorder like ASD with a continuum of phenotypes, where multiple variants add to the risk and severity of the disease. The weakness of this model is the lack of replication of statistically significant variants, suggesting the need to increase sample sizes.

**SCHZ pathology**

SCHZ is a debilitating and heterogeneous psychiatric disturbance characterised by delusions, hallucinations, psychotic episodes, loss of interest, social withdrawal and cognitive impairment. The first symptoms of SCHZ typically appear in late adolescence or early maturity, although they are preceded by signs suggesting an earlier origin of the disease. Some of the symptoms may be intermittent, with periods of remission, but the combined pathology has a profound social impact, as indicated by the 80%–90% unemployment rates among patients. Importantly, patients with SCHZ show abnormal function of multiple organs and metabolism and their life expectancy is reduced by 10–20 years. These symptoms are independent of the toxic effects of antipsychotic medication, suicide and poor health, suggesting a systemic disturbance that causes accelerated ageing, a connection with neurodegenerative diseases worth exploring. In addition, SCHZ symptoms are heterogeneous, overlap with other psychiatric conditions, or are secondary to other diseases or medication, complicating its diagnosis and study, thus delaying research. Current SCHZ treatments include antipsychotic drugs and behavioural therapies, although
long-term use of antipsychotics causes neurotoxicity and has serious side effects that lead to poor adherence,\textsuperscript{23} revealing a prominent gap in the treatment of SCHZ.

As with ASD, there are no diagnostic tests for SCHZ and no specific brain pathology implicating any particular part of the brain.\textsuperscript{1} However, the cognitive deficits implicate the prefrontal cortex and many brain regions experience subtle, progressive neuronal loss, particularly the temporal lobe, caudate nucleus and thalamus.\textsuperscript{25} However, no brain changes are specific and diagnostic for SCHZ, supporting the complex and heterogeneous pathology of this condition. Pharmacological studies suggest that aberrant dopamine neurotransmission is implicated in the psychotic symptoms, although these abnormalities are also present in other conditions.\textsuperscript{27} Abnormal glutamate neurotransmission also seems to be implicated in SCHZ, particularly in the cognitive impairment.\textsuperscript{2} The picture emerging from these data suggests diffuse and widespread brain dysfunction due to abnormal activity of dopaminergic and glutamatergic systems, aberrant connectivity possibly implicating interneurons and altered glia function due to inflammation and other stressors.\textsuperscript{2} A combination of genetic and environmental factors can perturb critical pathways during brain development leading to abnormal maturation that manifests fully in early adults.

Genetics and epidemiology of SCHZ
Originally, SCHZ was viewed as an alteration in early brain development (neurodevelopmental theory) that prevented full brain maturation.\textsuperscript{29} 30 More recently, a two-hit model was proposed to explain the heterogeneity in SCHZ with an early developmental component and a later hit that triggered the symptoms.\textsuperscript{31} 32 Currently, a multihit model that combines multiple genes and environmental factors that perturb brain development during key milestones seems to better describe the complexity of SCHZ,\textsuperscript{13} a theory that bears many similarities with ASD.

As with ASD, SCHZ has strong heritability, with as much as 80% of disease risk according to twin studies,\textsuperscript{34} but genetics alone does not explain all the disease risk. Additional environmental factors seem to contribute to SCHZ risk and, in combination with genetic factors, seem to better explain disease heterogeneity and complexity. A variety of social and environmental factors increase the risk of SCHZ, including social defeat, childhood trauma, social cognition, nutrition, smoking, cannabis use, low IQ, vitamin D deficiency and infection/neuroinflammation affecting the mother during pregnancy (see below).\textsuperscript{35} Each of these conditions likely have small effects, but combined with genetic variants at sensitive neurodevelopmental stages can alter brain development enough to cause SCHZ symptoms in early adulthood.

Recent advances in genetics support the complexity and polygenicity of SCHZ. GWAS have identified SNPs in over 100 common variants with small effects representing hundreds of genes. Note that 50%–66% of heritability of SCHZ arises from common variants, indicating their importance.\textsuperscript{35} 36 Combining these variants is expected to have significant contribution to disease, but studies have not yet confirmed how these genes work together to induce neurodevelopmental deficits. One of the consortia studying SCHZ identified 108 genes associated with SCHZ from GWAS,\textsuperscript{37} a limited number of candidate genes that will allow monographic studies searching for causative mutations. This set of SCHZ loci was enriched in genes expressed in the brain and in immune tissues, which agrees with previous data suggesting critical roles for neural development, synaptic function and immunity in disease risks/mechanisms. An independent study performed targeted sequencing of 2500 candidate genes and identified mutations in genes implicated in voltage-gated calcium ion channels, cytoskeletal complexes in the postsynaptic density and targets of FMRP,\textsuperscript{38} which narrow the candidate genes and pathways that should be further tested in disease models.

In addition to SNPs, 11 CNVs have a strong contribution to SCHZ, with 4% of patients carrying a CNV. A 3 Mb deletion at 22q11.2 is associated with SCHZ in 25% of the cases and a duplication of this region seems to protect against SCHZ.\textsuperscript{38} 39 It is unclear whether these CNVs contain a dose-sensitive gene, where a deletion or a duplication confer significant risk for SCHZ or contain several genes with a cumulative risk. In both cases, their strong contribution makes them highly valuable as we will discuss below. Most CNVs in psychiatric disorders are de novo mutations that are not inherited from the parents,\textsuperscript{40} which is consistent with the decreased life expectancy and fecundity in patients with SCHZ. Exome sequencing recently found that de novo mutations are enriched in postsynaptic genes implicating cytoskeletal and NMDA (N-methyl-D-aspartate) receptor complexes and targets of FMRP.\textsuperscript{40} The pathways disrupted by de novo mutations overlap with the SCHZ genes identified by GWAS and with other sets identified for ASD and ID, supporting a shared pathology in severe psychiatric disorders.

Overlap between ASD and SCHZ
ASD and SCHZ overlap in some symptoms, like ID, but the core phenotypes and the onset are disease specific. To the naive observer, this would suggest distinct pathogenic mechanisms for ASD and SCHZ and, therefore, the implication of different causative genes and environmental factors. Surprisingly, the dedicated genetic studies of the last few years have revealed significant similarities between ASD and SCHZ, including genetic variants, gene networks and environmental factors. Among the genetic variants, there is a common CNV for both ASD and SCHZ: the 3 Mb 22q11.2 region associated with the Phelan-McDermid syndrome. 22q11 deletions increase the risk for ASD, SCHZ and ID\textsuperscript{38} 39 41 and 22q11 duplications also increase the risk for ASD and ID but seem to protect against SCHZ.\textsuperscript{42} 43 Although CNVs like this contain hundreds of genes, the association of 22q11 with a developmental disorder and psychiatric conditions is highly suggestive of shared genetic mechanisms.

Despite the strong heritability of both ASD and SCHZ, around 50% of disease risk is unaccounted for, suggesting the contribution of environmental factors. One of the most significant overlaps between ASD and SCHZ relates to the involvement of chronic inflammation and neuroinflammation in early development, particularly in conditions affecting pregnant women.\textsuperscript{2} 33 Expectant mothers with autoimmune disorders or suffering infections at specific times during gestation have a higher risk of having children with ASD and ID\textsuperscript{44} 45 The presence of autoantibodies from the mom can alter early brain development of the baby, although these antibodies have been detected in the absence of autoimmune disease in the mother.\textsuperscript{2} Moreover, chronic immune changes have also been observed in individuals affected with ASD, implicating autoimmunity and the presence autoantibodies reactive to brain cells, increased cytokines and impaired immune cell response following an immune challenge (reviewed in ref. 2). Moreover, increased levels of cytokines in the brain are proposed to interfere with synaptogenesis. Even the microbiota seems to associate with ASD, suggesting a connection between immune system maturation and brain development (reviewed in ref. 2). Similarly, stressors such as childhood trauma and social
defeat can cause inflammation and altered neurotransmitter release and contribute to SCHZ. More importantly, several environmental stressors can activate human endogenous retroviruses (HERV); these HERV proteins and antibodies against them induce neuroinflammation that can be problematic during sensitive stages of development. In addition, maternal stress and infections also raise the risk for SCHZ, supporting a developmental component in SCHZ. Overall, these genetic and environmental risks support the shared mechanisms in ASD and SCHZ and reveal the impact of altered autoimmunity in brain developmental, particularly during gestation.

Altered gene expression in ASD and SCHZ
Several genes implicated in the regulation of gene expression are mutated in ASD and SCHZ (table 1). These genes regulate vital cellular activities such as chromatin remodelling, transcription and translation, and the targets of these genes are highly diverse and affect multiple cellular processes. Altered gene expression is particularly critical in neurons because activity-dependent gene expression plays key roles in plasticity and remodelling. The best-studied gene associated with autism is MECP2, which encodes a protein that binds methylated DNA and represses transcription, resulting in the epigenetic control of gene expression. MECP2 is on the X chromosome and its deletion causes Rett syndrome in boys and girls. Lack of MECP2 results in de-repressed transcription, whereas excess of MECP2 can perturb activity-dependent gene expression. Another example of syndromic autism is the loss of FMR1 function in fragile X syndrome, which presents with mental retardation and autism. FMRP is an RNA-binding protein that regulates mRNA shuttling and translation, thus controlling the amounts of mature mRNA that are translated. Mutations in both MECP2 and FMRP suggest that reduced levels of gene expression or reduced capacity to respond timely to activity-dependent gene expression demands results in altered brain development with severe consequences, including ASD, ID and progressive loss of locomotor skills. The function of these proteins and the severe defects in early development suggest the involvement of many potential targets, which complicates the identification of specific mechanisms and therapeutic targets.

Mutations in other genes involved in gene expression regulation in patients with ASD, including myocyte-specific enhancer factor 2C (MEF2C), histone deacetylase 4 (HDAC4), chromodomain-helicase-DNA-binding protein 8 (CHD8) and catenin β1 (CTNNB1), further support the role of altered gene expression in ASD pathogenesis (reviewed in ref. 10). De novo mutations in MEF2C identified in ASD cause LOF of MEF2C, which is a negative regulator of synapse number. The increase in synapse density in mice carrying MEF2C LOF mutations supports the role of gene expression regulation in synaptic plasticity and remodelling during brain development. Building neuronal networks requires the ability to modulate synapse number and strength to adequately respond to stimuli; thus, cellular mechanisms that increase or decrease synapse stability impact the maturation of time-sensitive brain networks. Interestingly, CHD8 is a negative regulator of CTNNB1 and both seem to regulate brain growth. Animal models expressing abnormal levels of CHD8 or CTNNB1 show changes in brain size, suggesting a role in neuroblast proliferation, differentiation and maturation.

The most interesting development in this area has been the recent report of several LOF mutations in SETD1A (SET domain containing 1A) in patients with SCHZ, including de novo mutations identified by exome sequencing. SETD1A is the catalytic subunit of a histone H3K4 histone methyltransferase complex (COMPASS) that regulates chromatin structure and gene expression, supporting the role of epigenetic regulation in SCHZ. Patients carrying SETD1A mutations also showed other neurodevelopmental phenotypes, including ID, developmental delay and epilepsy. De novo mutations in other genes implicated in gene expression regulation, including ZNF804A, TRRAP, UBR5, KDM2B and KDM5C, have been proposed recently, but no replication studies have confirmed their role in SCHZ with a high degree of confidence. Interestingly RBBP5 is another subunit of the COMPASS complex, while two other COMPASS subunits (KMT2A and KMT2C) and a direct interactor with the COMPASS complex (CHD8) harbour mutations in patients with ASD, strengthening the shared mechanisms in ASD and SCHZ.

Overall, alterations in gene expression regulation cause ASD and SCHZ together with other neurodevelopmental and psychiatric disorders, like ID and epilepsy, suggest widespread perturbations in brain development. However, these conditions have no clear disruption of brain anatomy; hence, the defects induced are subtle, involving altered synapse number and strength with the expected perturbations in synaptic plasticity and remodelling. The involvement of chromatin remodelling factors and epigenetic regulators of gene expression suggest the potential misregulation of large numbers of target genes. However, these ASD and SCHZ genes seem to converge in altered synaptic plasticity and remodelling during development. The ability to reshape synaptic function and connections is key for neuronal activities such as learning, but it is particularly critical during fetal development and childhood because of the continuous growth of the brain and the significant demands from new external stimuli. Altering the chromatin landscape or the composition and activity of transcriptional and translational complexes will delay transcriptional and translational responses to developmental and environmental stimuli. The slow building or pruning of synapses may alter critical developmental windows leading to irreparable errors during the maturation of neuronal circuits that can produce symptoms in early childhood (ASD) or early adulthood (SCHZ). Additional validation of causative genes controlling gene expression and modelling in animal models and induced pluripotent stem cells will clarify the molecular mechanisms leading to these psychiatric disturbances.

Altered synaptic activity in ASD and SCHZ
ASD and SCHZ are neurodevelopmental disorders without obvious morphological brain abnormalities. In the absence of macroscopic alterations, subtle but widespread perturbations at the cellular level have been proposed to underlie both pathologies. Current models suggest that aberrant neuronal connectivity, synaptic plasticity and/or synapse remodelling are at the core of the cellular pathologies of ASD and SCHZ. In support of the altered neuronal activity, several core symptoms of ASD (anxiety, depression and/or obsessive compulsive disorder) can be treated with selective serotonin reuptake inhibitors (SSRIs). Similarly, the symptomatic treatment of SCHZ includes antipsychotic medications that block dopamine transmission. These treatments indicate a strong role for altered neurotransmission in ASD and SCHZ. Thus, identifying additional mutations in genes implicated in neuronal function and synaptic activity would support a hypothesis based on deficient neurotransmission in ASD and SCHZ. In fact, recent studies have identified numerous candidate genes by GWAS and de novo mutations in synaptic genes in both conditions, although no causative mutation has been identified in this group with high confidence so far.
Many ASD-risk genes identified in recent efforts encode proteins involved in neuronal activity and synaptic architecture, including neurotransmission by glutamate (GluN2B), gamma-amino butyric acid (GABA) (GABRA3) and glycine (glycine receptor subunit α2); neurotogenesis (Contactin 6); cell adhesion molecules that confer neuronal identity (cadherins); neuronal conduction (Contactin-associated protein-like 2); calcium and sodium channels (CACNA1, SCN1A) and the activity-driven synapse formation regulators neurexin and neurolgin (reviewed in ref. 10) (see online supplementary table 1). In addition to these proteins implicated in cell adhesion and neurotransmission, the structure and function of the presynaptic and postsynaptic domains depend on the activity of scaffolding and cytoskeletal proteins. Three genes of the SH3 and multiple ankyrin repeat domains protein (SHANK) family are found

### Table 1  ASD and SCHZ genes implicated in gene expression regulation

<table>
<thead>
<tr>
<th>Gene</th>
<th>Name/protein</th>
<th>Function</th>
<th>Risk/other disease</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chromatin remodelling, transcription, translation</td>
<td>MEC2P</td>
<td>Methyl-CpG-binding protein 2</td>
<td>Histone methylation, chromatin remodelling, transcriptional repression</td>
<td>↑ ASD + Rett syndrome</td>
</tr>
<tr>
<td>FMR1</td>
<td>Fragile X mental retardation 1/FMRP</td>
<td>mRNA binding, maturation, transport to cytosol</td>
<td>↑ ASD + fragile X syndrome</td>
<td>12</td>
</tr>
<tr>
<td>EIF4E</td>
<td>Eukaryotic translation initiation 4E</td>
<td>CYFIP1-EIF4E-FMR1 complex mediates translational repression</td>
<td>↑ ASD + fragile X syndrome</td>
<td>35, 40</td>
</tr>
<tr>
<td>CYFIP1</td>
<td>Cytoplasmic FMRP-interacting protein 1</td>
<td>CYFIP1-EIF4E-FMR1 complex mediates translational repression</td>
<td>↑ ASD +SCHZ + fragile X syndrome</td>
<td>35, 40</td>
</tr>
<tr>
<td>MEF2C</td>
<td>Myocyte-specific enhancer factor 2C</td>
<td>MEF2 transcription factor family, regulates synapse number</td>
<td>↑ ASD in de novo mutations</td>
<td>77</td>
</tr>
<tr>
<td>HDAC4</td>
<td>Histone deacetylase 4</td>
<td>Histone deacetylation, chromatin remodelling, transcriptional repression</td>
<td>ASD</td>
<td>78</td>
</tr>
<tr>
<td>CHD8</td>
<td>Chromodomain-helicase-DNA-binding protein 8</td>
<td>Transcriptional regulator, represses CTNNB1, regulates brain growth, interacts with COMPASS</td>
<td>↑ ASD in de novo mutations + macrocephaly</td>
<td>57, 58</td>
</tr>
<tr>
<td>CHD7</td>
<td>Chromodomain-helicase-DNA-binding protein 7</td>
<td>Transcriptional regulator, positive regulator of RNA biogenesis</td>
<td>ASD + CHARGE syndrome</td>
<td>79</td>
</tr>
<tr>
<td>KMT2A</td>
<td>Lysine (K)-specific methyltransferase 2A</td>
<td>Subunit of Histone methyltransferase COMPASS complex</td>
<td>ASD in de novo mutations</td>
<td>57, 58</td>
</tr>
<tr>
<td>KMT2C</td>
<td>Lysine (K)-specific methyltransferase 2C</td>
<td>Subunit of Histone methyltransferase COMPASS complex</td>
<td>ASD in de novo mutations</td>
<td>57, 58</td>
</tr>
<tr>
<td>SMARCC1,2</td>
<td>SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin C1 and 2</td>
<td>Chromatin remodelling, regulates neurogenesis</td>
<td>ASD variants</td>
<td>57</td>
</tr>
<tr>
<td>SMARCA2</td>
<td>SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin A2</td>
<td>Chromatin remodelling, regulates neurogenesis</td>
<td>SCHZ variants</td>
<td>80</td>
</tr>
<tr>
<td>TBR1</td>
<td>T-box brain 1</td>
<td>Transcription factor, regulates neurogenesis</td>
<td>↑ ASD in de novo mutations</td>
<td>81</td>
</tr>
<tr>
<td>FOXP1</td>
<td>Forkhead Box P1</td>
<td>Transcription factor, mTOR signalling</td>
<td>ASD in de novo mutations</td>
<td>73</td>
</tr>
<tr>
<td>CTNNB1</td>
<td>Catenin J1</td>
<td>Transcription factor, activates WNT and regulates brain growth</td>
<td>ASD</td>
<td>57, 58</td>
</tr>
<tr>
<td>EIF4E</td>
<td>Eukaryotic translation initiation factor 4E</td>
<td>cap-dependent translation downstream of mTOR. Regulates other ASD genes with synaptic roles</td>
<td>ASD variants</td>
<td>82</td>
</tr>
<tr>
<td>TAF1L</td>
<td>TAF1 RNA pol II, TATA box binding protein (TBP)-associated factor</td>
<td>RNA pol II-mediated transcription</td>
<td>ASD in de novo mutations</td>
<td>73</td>
</tr>
<tr>
<td>TAF13</td>
<td>Transcription initiation factor TFIIID subunit 13</td>
<td>RNA pol II-mediated transcription</td>
<td>SCHZ de novo mutations</td>
<td>40</td>
</tr>
<tr>
<td>SETD1A</td>
<td>SET domain containing 1A</td>
<td>Subunit of histone methyltransferase COMPASS complex</td>
<td>↑ SCHZ, several mutations</td>
<td>55, 63</td>
</tr>
<tr>
<td>RBBP5</td>
<td>Retinoblastoma-binding protein 5</td>
<td>Subunit of Histone methyltransferase COMPASS complex</td>
<td>SCHZ variants</td>
<td>84</td>
</tr>
<tr>
<td>C7orf60</td>
<td>Probable methyltransferase BTM2 homologue</td>
<td>Probable S-adenosyl-L-methionine-dependent methyltransferase</td>
<td>SCHZ de novo mutations</td>
<td>40</td>
</tr>
<tr>
<td>TRRAP</td>
<td>Transformation/transcription domain-associated protein</td>
<td>Component of the NuA4 histone acetyltransferase complex</td>
<td>SCHZ variants</td>
<td>85</td>
</tr>
<tr>
<td>UBR5</td>
<td>E3 ubiquitin-protein ligase</td>
<td>Promotes accumulation of ‘Lys-63’-linked histone H2A and H2AX at DNA damage sites</td>
<td>SCHZ variants</td>
<td>83</td>
</tr>
<tr>
<td>KDM2B</td>
<td>Lysine (K)-specific demethylase 2B</td>
<td>Demethylates ‘Lys-4’ and ‘Lys-36’ of histone H3</td>
<td>SCHZ variants</td>
<td>83</td>
</tr>
<tr>
<td>KDMSC</td>
<td>Lysine (K)-specific demethylase 5C</td>
<td>demethylates ‘Lys-4’ of histone H3</td>
<td>SCHZ variants</td>
<td>83</td>
</tr>
</tbody>
</table>

ASD, autism spectrum disorder; SCHZ, schizophrenia; SWI/SNF, switching/sucrose non-fermenting; FMRP, Fragile X mental retardation protein; mTOR, mammalian target of rapamycin.
altered in patients with ASD and SHANK3 is included in the 22q11 deletion that confers high risk for ASD and SCHZ. SHANKs are scaffolding proteins that interact with glutamate receptors and the actin cytoskeleton and LOF of SHANK reduces the accumulation of actin in synapses, which alters axonal growth and synapses maturation. Mice harbouring mutations in Shank1, Shank2 or Shank3 present autistic-like phenotypes (self-injury, anxiety, repetitive behaviours) and decreases social interaction. These may be the most faithful genetic models of pure ASD described so far, indicating that the structural instability of the synapse is a key contributor to ASD.

As in ASD, many SCHZ-risk genes identified by GWAS are implicated in synaptic activity, including several involved in glutamate neurotransmission as well as several voltage-gated calcium channel subunits (same channel implicated in ASD, but different subunits) (see online supplementary table 1). Exome sequencing also identified de novo mutations enriched in the NMDA receptor complex and proteins that interact with ARC (activity-regulated cytoskeleton-associated protein) and DLG4 (Disc-large 4). Revealingly, several studies and a meta-analysis have confirmed variants associated with Dopamine receptor 2 (DRD2), including a deletion in its promoter that reduces DRD2 expression. DRD2 is the target of anti-psychotic medications prescribed to patients with SCHZ and ASD, suggesting a mechanism linking symptoms, pharmacology and genetics. However, the contribution of each polymorphism to SCHZ risk is small and more studies will need to uncover causative DRD2 mutations or combinations with other risk variants that significantly increase the risk of SCHZ.

Overall, defects in both excitatory (glutamatergic, dopaminergic) and inhibitory (GABAergic) neurotransmission contribute to ASD and SCHZ, suggesting alterations in the excitation/inhibition balance. This perturbation may have developmental (cell identity, connectivity) and/or physiological (plasticity and remodelling) bases.

**Immune system perturbations in ASD and SCHZ**

Evidence has gradually accumulated for a contribution of immune dysregulation to ASD, SCHZ and other psychiatric disorders. This connection led to the myth that vaccines given to infants cause ASD, a claim that has been debunked in numerous studies after putting many children at risk of preventable diseases. The innate immune system is designed to detect and respond to environmental threats, while the adaptive immune system prepares against future attacks. These peripheral immune cells are not expected to enter the brain; excess of immune cells and their products (antibodies and cytokines) can affect brain development and function, and in some cases have harmful effects. In addition to the exogenous factors linking ASD and SCHZ with immune activation listed above, recent genetic discoveries further support the contribution of the immune system.

The major histocompatibility complex (MHC) contains one of the major regions conferring risk for ASD and SCHZ. The 3.6 Mb MHC contains many complex loci with different copy numbers that makes its analysis particularly challenging. The MHC produces several human leucocyte antigen (HLA) and complement proteins critical for adaptive immunity. Recent efforts identified HLA variants conferring high risk for ASD and causative mutations for SCHZ. Among these, the HLA-A1 haplotype confers high risk for ASD and alleles for HLA-DRB1 combined with autoimmune disorders increase the risk for ASD. More revealing are deficiencies in the MHCIII region affecting a complement gene, C4B. Loss of complement function is expected to increase autoimmune responses through the production of autoantibodies with harmful consequences. In addition, mutations in members of the IL-1 cytokine receptor family are associated to ASD. Exome sequence has identified synonymous SNPs in the IL-1β decoy receptor IL-1 type 2 (IL-1R2), although the functional consequences of this variant are not known at this time. Mutations and CNV causing LOF in IL-1 receptor accessory protein-like 1 (IL-1RAPL1) are also linked to ASD and ID, indicating the convergence of several psychiatric disorders in the immune system (table 2).

Although very revealing, all these MHC variants still need to be confirmed for causality of ASD.

The strongest genetic association for SCHZ by far resides in the MHC locus and the SCHZ-related variants accumulate throughout the complex. However, the accumulation of variants in the region containing the C4 gene made it a candidate for directed studies. Human C4 encodes two genes, C4A and C4B, each has multiple copies with long and short isofoms depending on the integration of a HERV. CNV and HERV variant suggested a potential role for significant changes in the expression levels of C4A and C4B. A report published this year found a strong correlation between SCHZ variants and elevated levels of C4A, suggesting a potential mechanistic link to disease pathogenesis. Apparently, elevated activity of C4A can interfere with neuronal maturation and circuit formation. C4 is known to activate C3, which binds to receptors in synapses and regulates pruning by microglia during development and is required for synaptic remodelling later on. Experiments in mice support this hypothesis because C4 mutant mice show low levels of C3 in synapses and reduced pruning. Thus, deficient synaptic pruning due to high levels of C4A perturb brain development, maturation and plasticity, which can explain the strong genetic connection between SCHZ and the MHC. Interestingly, while high C4A is linked to SCHZ, low C4B expression is linked to ASD, intimately connecting these complex psychiatric conditions at the genetic and mechanistic levels. This overlap, hence, supports the idea that alterations of the immune system during sensitive developmental stages have prominent effects in early brain development, resulting in the dramatic manifestations of ASD and SCHZ.

**Concluding remarks**

The strong genetic component of ASD and SCHZ was well known for some time, but only recent collaborative efforts using cutting-edge sequencing technology have successfully identified candidate loci and causative genes leading to emerging mechanisms for these severe psychiatric conditions. Although large numbers of candidate genes have been identified so far by GWAS, the relevance for most genes is still unclear lacking replication studies, causative mutations or animal models that demonstrate causality. GWAS typically identify non-coding loci with potential function in the regulation of distant genes. Thus, the path form GWAS loci to causative gene is typically long and leads to many dead ends and frustration. But the picture described here indicates strong contributions of the cellular machineries regulating gene expression, synaptic architecture and activity and immunity. The implication of genes involved in maintaining the synaptic architecture and activity, including cytoskeletal proteins, neurotransmitter receptors and activity-dependent pathways, strongly support abnormal neuronal connectivity and synaptic activity as the cellular basis of ASD and SCHZ. These mechanisms are consistent with the absence of macroscopic changes in the brain of patients, suggesting instead the contribution of diffuse perturbations at the cellular
As discussed above, these advances in understanding the cellular and molecular basis of psychiatric pathologies will provide a rational approach to therapeutics. In simple, monogenetic diseases, the obvious therapeutic target would be the mutant gene, because correcting the deleterious consequences of the mutation should eliminate all the symptoms. Alternatively, downstream factors mediating the phenotypes are the obvious targets for therapeutics. In the case of ASD, SCHZ and other polygenic disorders, identifying the targets is more complex since different genetic variants and environmental factors can combine to trigger pathogenesis. In this situation, personalised genomics can help evaluate the triggers in each individual to tailor the available treatments. When no obvious mutations are detected, understanding that all the risk factors converge in altered connectivity and synaptic activity can lead to the development of drugs that specifically correct these deficits at the transcriptional or synaptic level. Overall, the advances in the genetics of ASD and SCHZ in recent years are exciting and provide strong molecular basis to focus on specific therapies, particularly in ASD.

Acknowledgements The authors are thankful for the secretarial assistance and for all the suggestions from friends and collaborators for improving the manuscript. Xiaoming Liu and Zhengwei Li contributed equally to this article.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

© Article author(s) (or their employee(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Neurogenetics

REFERENCES


75 Takahashi H, Craig AM. Protein tyrosine phosphatases PTPdelta, PTPxianga, and LAR: presynaptic hubs for synapse organization. Trends Neurosci 2013;36:522–34.


Genetics implicate common mechanisms in autism and schizophrenia: synaptic activity and immunity

Xiaoming Liu, Zhengwei Li, Conghai Fan, Dongli Zhang and Jiao Chen

*J Med Genet* 2017 54: 511-520 originally published online March 17, 2017
doi: 10.1136/jmedgenet-2016-104487

Updated information and services can be found at:
http://jmg.bmj.com/content/54/8/511.2

These include:

**References**
This article cites 96 articles, 8 of which you can access for free at:
http://jmg.bmj.com/content/54/8/511.2#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Editor’s choice (124)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/